Pancreatic cancer patients with the most common KRAS mutation appeared to have a lower response rate than the overall patient ...
City Therapeutics eyes $158M IPO; Iambic Therapeutics targets $135M; Alchemist Capital launches with $100M; Life Biosciences ...
Curium prices Bexlutry, its copycat of Novartis’ radioligand Lutathera, at $63,524 per infusion, about 5% below the original.
IPOs on Nasdaq, backed by Eli Lilly, focusing on Treg science for autoimmune disorders. Pipeline includes TRB-061 and a CD30 agonist for IBD.
Plus news about Denali, Nuvectis Pharma, Graph Therapeutics, GondolaBio and the Novo Nordisk Foundation. 🔗 Eli Lilly’s alliance with BioArctic: The Indianapolis drug giant will ...
PhRMA says FDA will get money it can spend only on hiring and keeping staff, to restore reviewer levels after the HHS layoffs ...
WHO releases preeclampsia roadmap; Comanche, DiaMedica, Avilar & ProFound developing treatments; Eli Lilly exploring the ...
Biohaven licenses pan-IgG degraders to Ono for $80M; UK pulls Ixchiq; ADC raises $86.6M; BMS Zenbexus Phase 3 win; Pfizer ...
Chan Zuckerberg Biohub launches $1.8B Virtual Biology Initiative with Meta, Google DeepMind, Isomorphic Labs, DOE, and NIH to ...
Ultragenyx sells a rare pediatric disease PRV for $210M, one of 2026's priciest voucher deals, and plans to monetize a second ...
Petrelintide reduced patients’ average body weight by up to 9.2%, compared to 2.0% among those who received placebo.
The World Health Organization on Wednesday recommended against GLP-1 drugs for children with obesity who are under 10 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results